Altasciences
A Canadian-origin contract research organization with the largest disclosed CRO canine colony in the United States, wholly owned by Novo Holdings since 2021.
Company Overview
Altasciences traces its origins to Algorithme Pharma, a bioanalytical and clinical pharmacology firm founded around 1992 with roots at the Université de Montréal. The company is headquartered in Laval, Quebec, and operates nine facilities spanning preclinical toxicology, clinical research, and bioanalytical services across the United States and Canada.
The company grew through an aggressive buy-and-build strategy under successive private equity owners. Kilmer Capital Partners held the platform beginning around 2013, adding Vince & Associates (a Kansas City clinical unit). Audax Private Equity acquired the business in 2017 and accelerated acquisitions, including the pivotal purchase of SNBL USA's preclinical operations in Everett, Washington, and expansion into Pennsylvania and Missouri.
In March 2021, Novo Holdings — the investment arm of the Novo Nordisk Foundation — acquired 100% of Altasciences for approximately DKK 2.25 billion (~$340 million). The company is privately held and does not disclose revenue figures. Leadership shifted in February 2026 when Marie-Hélène Raigneau was appointed CEO, with Chris Perkin moving to executive chair.
The Novo Holdings Ownership Chain
The ownership structure creates a direct link between one of the world's largest pharmaceutical companies and a major canine-testing CRO:
Beagle & Canine Operations
Altasciences operates three U.S. preclinical facilities with disclosed canine housing capacity. A fourth site in Sacramento focuses on NHP translational research. USDA annual report data for FY2023 reveals dog populations significantly exceeding stated capacity at some sites:
Combined FY2023 dog count: 1,931 dogs across the three USDA certificates — making Altasciences the largest disclosed CRO canine colony by publicly available data. The Auxvasse facility alone housed 923 dogs against a stated capacity of ~700, a 32% overage.
Study Types & Specializations
Investigations & USDA Violations
USDA APHIS issued a formal warning to Altasciences Preclinical Seattle LLC for an alleged handling violation under 9 C.F.R. § 2.38(f)(1)— the federal standard requiring that handling of animals must be done in a manner that avoids trauma, behavioral stress, physical harm, or unnecessary discomfort. Official warnings represent a step beyond routine inspection citations and signal that APHIS determined a documented violation warranted formal enforcement action.
USDA FOIA logs reference an enforcement investigation involving four Animal Welfare Act critical citations for the Everett facility (certificate 91-R-0075). Critical citations are the most severe category in USDA's inspection framework, indicating conditions that directly compromise animal health, welfare, or safety. The specific nature of the violations has not been fully disclosed in publicly available records.
- Full USDA inspection reports for all three canine facilities not yet obtained via FOIA
- Species-specific violation details (whether dogs were the subjects) not confirmed in public records
- No public disclosure of IACUC composition or independence at any Altasciences facility
The Related-Party Conflict Question
The ownership chain creates a textbook related-party framework: the Novo Nordisk Foundation controls both Novo Nordisk (76.9% voting rights via Novo Holdings) and Altasciences (100% via Novo Holdings). The Foundation's own financial disclosures list both entities as related parties.
The core question: Does Novo Nordisk contract Altasciences for preclinical canine studies? CRO client engagements are confidential, and neither party publicly itemizes vendor use at the study-provider level. The answer is not publicly confirmed — but the structural conditions for a conflict of interest exist, and the Foundation acknowledges related-party transaction frameworks in its reporting.
If the relationship exists, Novo Nordisk would be directing beagle testing to a laboratory it effectively controls through its parent foundation — raising questions about independent oversight, pricing transparency, and whether welfare standards are subject to genuine arms-length scrutiny.
Key People
Cross-Border Oversight Context
Altasciences is headquartered in Canada (CCAC voluntary peer-review model) while all dog-housing preclinical operations are U.S.-based under mandatory USDA Animal Welfare Act inspection. This split means the corporate parent operates under voluntary accreditation while its canine testing divisions face federal inspections. Whether uniform welfare standards apply across both regimes is not publicly documented.
Corporate Timeline
Open Data Gaps
- No public beagle retirement or adoption program page; no quantitative rehoming outcomes disclosed
- No breed-mix disclosure for canine colonies (beagle proportion vs. other strains unknown)
- Canine supplier identity undisclosed; alleged breeder linkages require document verification
- Novo Nordisk client relationship with Altasciences: not confirmed, not denied
- Complete USDA enforcement history requires additional FOIA beyond publicly posted records
- Revenue, study volume, and per-facility animal throughput figures are not publicly reported
Sources & References
- USDA APHIS: Annual reports (Form 7023) for certificates 43-R-0122, 91-R-0075, 23-R-0107; Official Warning Notice (Oct 2024); FOIA enforcement logs
- Novo Nordisk Foundation: 2022 Annual Report; consolidated financial statements listing related parties and ownership percentages
- Novo Holdings A/S: Investment portfolio disclosures; Altasciences acquisition announcement (Mar 2021)
- Altasciences: Corporate website; published literature referencing “conscious beagles” in CV telemetry; leadership announcements (Feb 2026)
- SNBL/Shin Nippon: Historical USDA registrations (91-R-0053, 91-B-0078); entity transfer documentation
- Industry reporting: PE transaction coverage (Audax, Kilmer); local journalism on Everett campus acquisition
Last updated: March 2026. This profile is based on publicly available records and does not include information obtained through confidential sources. Corrections and additions are welcome.